ClinicalTrials.gg
Active, not recruitingNCT06794281SYNTHEMA (SCD)Updated Mar 12, 2025

Synthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case

An observational study in Sickle Cell Disease, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Active, not recruiting at 3 sites in 3 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,500
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Anemia, Sickle Cell with a site in Italy — 9 open to participants now, 16 under way, 9 of them phase 3. Anemia, Sickle Cell · Italy.

Planned enrollment
5th of 10
1,500 · median 1,250
Started
2022
with 8 others
Observational
10 of 43
1 open now
Primary completion
2026-11
later than 5 of 15 live
Registered
41st of 43
by date
Lead sponsor
2 of 43
Hospital Universitari Vall d'Hebron Research Institute

Among the 43 studies in Anemia, Sickle Cell with a site in Italy, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is one of 9 that started in 2022, is one of 10 observational ones, reaches primary completion later than 5 of the 15 other live ones, and was the 41st registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

9 of the 43 studies in Anemia, Sickle Cell with a site in Italy are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Anemia, Sickle Cell with a site in Italy, or all of them as a file.
02

Study summary

Haematological diseases (HDs) are a large group of disorders resulting from quantitative or qualitative abnormalities of blood cells, lymphoid organs and coagulation factors. Despite most of them (\~74%) are rare, the overall number of HD affected patients worldwide is important, placing a considerable economic burden on healthcare systems and societies. Despite the existence of several collaborative research groups at national and EU level, current clinical approaches are often ineffective, particularly for rarest conditions, due to the relatively low number of patients per disease and the high number of unconnected clinical entities.

SYNTHEMA aims to establish a cross-border data hub where to develop and validate innovative AI-based techniques for clinical data anonymisation and synthetic data generation (SDG), to tackle the scarcity and fragmentation of data and widen the basis for GDPR-compliant research in rare hematological disorders (RHD). The project will focus on one representative RHD use case: sickle-cell disease (SCD).

Read the detailed description

SYNTHEMA will develop a federated learning (FL) infrastructure, equipped with secure multiparty computation (SMPC) and differential privacy (DF) protocols, connecting clinical centres bringing standardised, interoperable multimodal datasets and computing centres from academia and SME. This framework will be utilised to train the developed algorithms and perform SMPC-based global model aggregation in a privacy-preserving fashion. The resulting data will be validated for their clinical value, statistical utility and residual privacy risks. The project will develop legal and ethical frameworks to guarantee privacy by-design in the collection and processing of health-related personal data and attain an ethics-wise algorithm co-creation. Project outcomes, including pipelines, standards and data, will be made openly available to stakeholders in the healthcare, academia and industry field, and contribute to existing rare disease registries

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

SYNTHEMA will retrospectively collect existing RHD clinical, omics and imaging datasets from all the health data centres of its consortium (VHIR, UMCU, GLSMED LH, UNIPD) for the target SCD clinical use cases.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SCD patients (any genotype).
  • older than 1 year old

Exclusion criteria

Exclusion Criteria:

  • younger than 1 year old
  • post patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,500 participants (estimated)
Patient registry
No

Interventions

  • OtherGenerate synthetic multimodal (clinical, omics and imaging) data for rare haematological diseases with a validated clinical result

    O1. Provide novel methods and capabilities to generate synthetic multimodal clinical, omics and imaging data for SCD with a validated clinical result. O2. Develop de-identification, minimisation and anonymisation pipelines, including automatic assessment of privacy levels, at the service of clinical research and care. O3. Consolidate and scale-up the use of FL applications, SMPC and DP solutions for privacy-preserving local algorithm training and global model aggregation. O4. Ensure ethical and GDPR compliance in anonymised and synthetic data-driven research in RHDs. O5. Ensure wide uptake and scalability of the developed methodologies and tools through effective stakeholder engagement, dissemination and open science practices.

    Also known as: Synthetic Data Generation

06

What researchers measure

Primary outcomes

  1. Generate synthetic multimodal (clinical, omics and imaging) data for rare haematological diseases with a validated clinical result

    For Sickle Cell Disease, validation scenarios will test the reliability of synthetic data in regards to genomic variants/disease phenotypes association and MRI feature-based prediction of brain vascular events (SCD).

    Time frame: November 2026

07

Study locations

3 sites
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2025
First posted
Jan 27, 2025
StartActual
Nov 1, 2022
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06794281
Collaborators
Universidad Politecnica de Madrid, Datawizard SRL, University of Southampton, Humanitas Mirasole SpA, Charite University, Berlin, Germany, Universita degli Studi di Padova, Assistance Publique - Hôpitaux de Paris, Vicomtech, GLSMED Learning Health S.A., UMC Utrecht, Intrasoft
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Nov 1, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Mar 12, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion